title: Canadian Association of Gastroenterology position statement regarding the use of thiopurines for the treatment of inflammatory bowel disease.
authors.forename: John K
authors.initials: JK
authors.lastname: Marshall
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Otley
authors.forename: Waqqas
authors.initials: W
authors.lastname: Afif
authors.forename: Charles N
authors.initials: CN
authors.lastname: Bernstein
authors.forename: Lawrence
authors.initials: L
authors.lastname: Hookey
authors.forename: Grigorios
authors.initials: G
authors.lastname: Leontiadis
authors.forename: Remo
authors.initials: R
authors.lastname: Panaccione
authors.forename: Brian
authors.initials: B
authors.lastname: Bressler
mesh_terms: D001379:Azathioprine / Q000009:adverse effects*; D002170:Canada; D005762:Gastroenterology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000473:pathology; D008113:Liver Neoplasms / Q000139:chemically induced / Q000517:prevention & control; D016399:Lymphoma, T-Cell / Q000139:chemically induced / Q000517:prevention & control; D015122:Mercaptopurine / Q000009:adverse effects*; D012955:Societies, Medical; D013160:Splenic Neoplasms / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D001379:Azathioprine